National Asset Management, Inc. Incyte Corp Transaction History

National Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$67.18 - $84.11 $604 - $756	-9 Reduced 0.28%	3,235 $259,000
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $1,257 - $1,574	-19 Reduced 0.58%	3,244 $217,000
Q2 2022 Aug 12, 2022	SELL	$66.18 - $83.18 $3,309 - $4,159	-50 Reduced 1.51%	3,263 $248,000
Q1 2022 May 02, 2022	BUY	$66.02 - $79.71 $3,829 - $4,623	58 Added 1.78%	3,313 $264,000
Q4 2021 Jan 28, 2022	BUY	$63.34 - $74.11 $10,387 - $12,154	164 Added 5.31%	3,255 $239,000
Q3 2021 Nov 16, 2021	SELL	$68.67 - $84.02 $7,691 - $9,410	-112 Reduced 3.5%	3,091 $213,000
Q2 2021 Aug 10, 2021	BUY	$79.87 - $87.53 $15,974 - $17,506	200 Added 6.66%	3,203 $270,000
Q1 2021 May 13, 2021	BUY	$76.02 - $100.5 $228,288 - $301,801	3,003 New	3,003 $244,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.